PharmaBiz -- A comprehensive analysis published in The Lancet, one of the world’s leading medical journals, from the Absorb clinical trial demonstrated that Abbott’s bioabsorbable drug eluting stent, currently in development, successfully treated coronary artery disease and was absorbed into the walls of treated arteries within two years. The two-year data also demonstrated that after the bioabsorbable device was absorbed, the treated blood vessels appeared to move and function similar to unstented arteries. Preliminary findings from the 30-patient Absorb trial were presented in October 2008 at the Transcatheter Cardiovascular Therapeutics annual meeting in Washington, D.C.
